Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JYOXZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
4D5-AF (CUAAC)
|
|||||
| Synonyms |
Anti-HER2 antibody-drug conjugates (MedImmune); HER2/neu monoclonal antibody-cytotoxic drug conjugate (Allozyne); AZ-05
Click to Show/Hide
|
|||||
| Organization |
Allozyne, Inc.; AstraZeneca PLC; MedImmune LLC
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-HER2/neu mAb 4D5
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Auristatin F
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N6-(2-azidoethoxy)carbonyl-L-lysine
|
Linker Info | ||||
| Conjugate Type |
4D5-AF conjugates were generated by copper catalyzed cycloaddition (CuAAC) with non-natural amino acid containing an azide moiety.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.